Selected article for: "ace effect and acute sars"
Author: Zhenhua Zeng; Tong Sha; Yuan Zhang; Feng Wu; Hongbin Hu; Haijun Li; Jiafa Han; Wenhong Song; Qiaobing Huang; Zhongqing Chen
Title: Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study
  • Document date: 2020_4_11
    • ID: lujxql3a_32
    Snippet: Unexpectedly, ACE2 also serves as the cellular entry point for the severe acute respiratory syndrome (SARS) virus and the enzyme is therefore a prime target for pharmacological intervention on coronavirus-related diseases 9 . In 2003, ACE2 was identified as the receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), which mediates the infection and transmission of SARS-CoV. This effect does not rely on the protease activity on ACE .....
    Document: Unexpectedly, ACE2 also serves as the cellular entry point for the severe acute respiratory syndrome (SARS) virus and the enzyme is therefore a prime target for pharmacological intervention on coronavirus-related diseases 9 . In 2003, ACE2 was identified as the receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), which mediates the infection and transmission of SARS-CoV. This effect does not rely on the protease activity on ACE 10 . Structural analysis showed that the spinous protein of SARS-CoV was in contact with the head-end of the ACE2 catalytic domain subunit I, did not involve subunit II, and did not block the active region. Once SARS-CoV is connected to ACE2, the extracellular part of ACE2 will be lysed, and the transmembrane part will be transferred into the cell, which mediates further fusion of the virus particles and host cells 11 . Through next-generation sequencing technology, the entire genome sequence of COVID-19 has been successfully determined 12 . Compared with the genomic sequences of previous coronaviruses, it is found that SARS-COV-2 has 79% similarity with SARS-CoV 13 .

    Search related documents:
    Co phrase search for related documents
    • active region and domain subunit: 1, 2
    • active region and enzyme SARS virus acute respiratory syndrome: 1
    • active region and genome sequence: 1
    • active region and host cell: 1, 2, 3
    • acute respiratory syndrome and coronavirus relate: 1, 2, 3, 4
    • acute respiratory syndrome and domain subunit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and entire genome sequence: 1, 2, 3, 4
    • acute respiratory syndrome and entry point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and enzyme SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and enzyme SARS virus acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and generation sequencing technology: 1, 2, 3, 4, 5
    • acute respiratory syndrome and genome sequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and genomic sequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and host cell virus particle: 1, 2, 3
    • acute respiratory syndrome and host cell virus particle fusion: 1, 2
    • acute respiratory syndrome and pharmacological intervention: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • catalytic domain subunit and domain subunit: 1, 2, 3, 4
    • domain subunit and host cell virus particle: 1